No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
RLMD250117P50000
- 49.40
- 0.000.00%
15min DelayTrading Dec 4 10:49 ET
0.00High0.00Low
0.00Open49.40Pre Close0 Volume0 Open Interest50.00Strike Price0.00Turnover1116.55%IV-66.20%PremiumJan 17, 2025Expiry Date49.64Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.6413Delta0.5510Gamma0.01Leverage Ratio-0.0063Theta-0.0076Rho0.00Eff Leverage0.0003Vega
Intraday
- 5D
- Daily
News
Relmada Therapeutics Shifts Focus After Study Discontinuation
Relmada Therapeutics Exploring Sale After Lead Program Failure
Express News | Relmada Therapeutics Inc: To Explore Strategic Alternatives
Express News | Relmada Therapeutics Inc: Will Continue to Advance Phase 1 Study of Rel-P11, an Investigational Agent for Treatment of Metabolic Disease
Express News | Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of Rel-1017
Press Release: Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017